Year: 2025

Amsterdam 10 December 2025 | The Magnum Ice Cream Company (TMICC; AEX: “MICC”), the world’s largest ice cream company, today confirmed its inclusion in the AEX Index on Euronext Amsterdam as of its first day of trading on 8 December. The announcement follows Euronext’s quarterly index review, which is based on criteria, including free-float and market capitalisation. The AEX Index comprises the 30 largest and most actively traded companies listed on Euronext Amsterdam and is the main index of the Dutch stock market. “As the global ice cream leader, headquartered in Amsterdam, The Netherlands – we are proud to be included alongside leading Dutch and international businesses as part of the AEX – Euronext Amsterdam’s premier index. As we begin life as a listed company, we look forward to engaging with investors and expanding the Ice Cream...

(10 December 2025 – Oslo, Norway) Reference is made to the stock exchange release by Hexagon Purus (“the “Company”) on 18 April 2023 and 25 October 2024, where Hexagon Purus Systems USA LLC, a subsidiary of the Company, signed a multi-year agreement for the supply of lithium-ion battery cells and the subsequent amendment of its terms. Hexagon Purus Systems USA LLC has today entered into a second amendment to the supply agreement with its battery cell supplier. Under this amended agreement, the previously outstanding pre-payment obligation of USD 12.9 million is removed in full, while continued supply of battery cells to Hexagon Purus is ensured. Furthermore, any Inflation Reduction Act (IRA) incentives or credits that may arise from the supplier’s production of battery cells will accrue to the supplier. For more information: Mathias Meidell, Investor...

New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertensionAllschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”.1 The analysis examined the efficacy and safety of aprocitentan (TRYVIO™/JERAYGO™) in patients with chronic kidney disease (CKD) and confirmed resistant hypertension – a population with very limited treatment options and high cardiovascular and renal risk. Aprocitentan, the first approved antihypertensive targeting...

Coop Pank’s financial results in November 2025:In November, the number of the bank’s customers increased by 1,800 and number of active customers increased by 1,000. By the end of the month number of customers reached 225,800 and number of active customers reached 107,800. Over the year, customer base has grown by 10%. Volume of the bank’s customer deposits increased by 24 million euros and reached 1.97 billion euros by the end of the month. Deposits of corporate customers increased by 22 million euros and deposits of private customers increased by 11 million euros. The volume of deposits attracted from international platforms decreased by 9 million euros. Over the year, volume of bank deposits has grown by 138 million euros, i.e. 8%.   The bank’s loan portfolio increased by 28 million euros and reached 2.06 billion euros...

Strategic highlights: Aegon announces ambition to become a leading US life insurance and retirement group Aegon to move its head office and legal seat to the US and be renamed Transamerica Inc. at completion of transition, which Aegon aims to conclude by January 1, 2028 Aegon Asset Management to focus on growing third-party revenues and improving efficiency Continued focus on profitable growth in Aegon’s International business Strategic review of Aegon UK, evaluating all options, including divestmentFinancial highlights:Achieving all financial targets for 2025 Further execution upon Aegon’s strategy to reduce capital employed in Financial Assets through a reinsurance transaction on part of its SGUL block, reducing mortality and policyholder behavior risk and capital employed by USD 0.3 billion. Negative impact on RBC ratio neutralized...

Press release – Regulated InformationIeper, Belgium – 10 December 2025, 07.00 hrs CET – Melexis NV (Euronext Brussels: MELE) (“Melexis”) announces a new share buy-back program. The share buy-back program initiated by Melexis NV on 11 December 2024 will expire today 10 December 2025. Melexis’ Board of Directors has decided to initiate a new share buy-back program of its outstanding common stock for up to an additional 850,000 shares for an amount of up to EUR 50 million. This follows the shareholders’ authorization granted in November 2023. The share buy-back program is scheduled to run from 11 December 2025 until 10 December 2026. Pursuant to the shareholders’ authorization purchases will be effected at a price which will comply with the legal requirements, but which will in any case not be more than 10% below the lowest...

(2025-12-10) Kitron is hosting a Capital Markets Presentation today to update investors on the company’s financial and commercial targets and ambitions. Reflecting accelerating defence demand and expanded capacity, Kitron is updating and extending its medium-term ambitions. Over the coming year, the company expects to approach its previously communicated revenue target of EUR 1 billion. Kitron now outlines the way forward to EUR 1.5 billion in revenue. Kitron’s strategy calls for this growth to be combined with an EBIT margin above 9 per cent and a return on operating capital above 25 per cent. “Europe is entering an investment supercycle in defence, and manufacturing and electronics have become strategic bottlenecks. Without a secure, high-reliability manufacturing and supply chain, no country can deliver modern platforms at the...

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali Therapeutics expects to receive total gross...

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $602.0 million, before deducting underwriting discounts and commissions...

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters’ option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected...